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Abstract 
Urinary tract infections are one of the most common causes of ambulatory care 
visits, physician-office visits and hospitalization each year in the US. Sexual activity 
primarily contributes to acquisition of UTI in women; nearly half of adult women have 
had a UTI at least once. The most common causative agent is E. coli, followed by 
Enterobacter spp., Klebsiella spp., Pseudomonas aeruginosa, Proteus mirabilis, other 
Gram-negative rods and Group B streptococci, depending on geographical location. 
1 
Until the late 1990's, trimethoprim-sulfamethoxazole (TMP-SMX) was the most 
commonly prescribed and effective treatment option, but the rampant development of 
resistance to this drug has caused the IDSA to mandate a switch to Cipro as the first-line 
empiric treatment. This study was designed to compare Cipro's efficacy to that ofTMP-
SMX and nitrofurantoin, comparing two samples in the greater Chattanooga area. The 
samples were used to study the relationship between various factors, such as age, sex, 
previous UTI, previous antimicrobial treatment, sexual activity and chronic illness, and 
UTI incidence and resistance. Total resistance to TMP-SMX was 17%, to nitrofurantoin, 
20%, and to Cipro, 8%. UTI incidence occurred in the order: Escherichia coOL> Klebsiella 
pneumoniae> Pseudomonas aeruginosa> Proteus mirabilis> Enterobacter spp, 
Citrobacter spp., and other Gram negative bacilli. Age was not found to be related to 
antimicrobial resistance in women, but may link to resistance in men. Sexual activity and 
menopause may be related to UTI incidence in both samples, while previous UTI, 
previous antimicrobial treatment and chronic illness may correlate with resistance. The 
Collegedale sample was too small to substantiate results. A study over a longer time 
period is needed to confirm these preliminary findings. 
Introduction: 
Urinary tract infections (UTI) account for approximately 4 million ambulatory-
care visits, 8 million physician-office visits, and 100,000 hospitalizations annually in the 
United States (CDC, 2000; O'Donnell et al., 2002). Sexually active women are at highest 
risk for the disease; about 40% to 50% of adult women report that they have had a UTI at 
least once in their life (Hooten, 1997). Conditions commonly associated with 
complicated urinary tract infections include kidney stones, urethral or prostatic 
obstructions, urethral stents, circumcision, micturation disorders, bowel disorders, 
immunosuppressive therapy, diabetes, pregnancy, age and sex (Gupta et al., 1999; 
Mangiarotti et al., 2000; O'Donnell et al., 2002). Symptoms range from painful urination 
and minor discomfort to abdominal and/or back pain, fever, decreased kidney function or 
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sepsis, which can become fatal in immunocompromised individuals (CDC, 2000). 
Infections may be minor (urethritis, cystitis, prostatitis), or "uncomplicated" infections of 
the lower urinary tract, or develop into more serious forms of disease, which may become 
systemic. Acute cystitis (bladder infection) and acute pyelonephritis (infection of the 
renal pelvis) are the most significant in terms of morbidity (Price and Wilson, 1997). 
Transmission usually occurs through fecal contamination of the urinary tract. E. 
coli, a normal inhabitant of the colon, is the most common causative agent in UTI, 
accounting for approximately 80% of reported cases (Price and Wilson 1997; Mangiarotti 
et al., 2000; Bukharie and Saeed, 2001). Other organisms commonly associated with 
UTI include Klebsiella spp., Staphylococcus saprophyticus, Proteus spp., Enterobacter 
spp., Citrobacter spp., Enterococcus spp., Candida spp., and Staphylococcus aureus 
(Gupta et al., 1999; Talan et al., 2000; Bukharie and Saeed, 2001). Rare cases of UTI 
have also been associated with the genera Hafnia, Serratia, Providencia, Morganel/a, 
Pseudomonas, Xanthomonas, and Alcaligenes, several of which exhibit alarming 
resistance to antimicrobial treatment (Thomson et al., 1994). 
Etiologic agents responsible for UTI seem to vary by location both in occurrence 
and prevalence. Mathai et al. (2001) collected thirty-two UTI pathogens from 1,510 
patients in 31 locations in the United States to determine national incidence rates in 1997 
and 1998. The species and rank order of specific agents identified during the study were 
slightly different than that obtained in a similar study by Bukharie and Saeed (200 1) in 
Saudi Arabia, and Table 1 compares the results of both. 
Most UTI cases may be cured with outpatient oral antimicrobial therapy. Until 
recently, ampicillin, amoxicillin, tetracycline, amikacin, and trimethoprim-
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sulfamethoxazole were the most common therapeutic agents prescribed for both 
uncomplicated and complicated UTI infections (Gupta et al. 1999; Bukharie and Saeed, 
2001). However, though studies reiterate the geographic variation in incidence of 
causative agents, one fact has become increasingly clear. Antimicrobial resistance in UTI 
pathogens is dramatically increasing. In the same study by Mathai et al. (2001) co-
resistance was elevated, though pathogen incidence did not change, for aminoglycosides, 
tetracyclines, sulfonamides, and fluoroquinolones. Bukharie et al., (2001) documented 
resistance for all isolates combined of more than 50% for ampicillin and tetracycline, and 
E. coli resistance of 39% for trimethoprim-sulfamethoxazole (TMP-SMX). In another 
study conducted over a four-year period, resistance to trimethoprim and TMP-SMX rose 
from 9% to 18% in E. coli and from 8% to 16% in all isolates combined (Gupta et al., 
1999). But even resistance varies geographically. In a recent study of acute 
uncomplicated pyelonephritis in women, 32% of isolates from Western states were 
resistant to TMP-SMX, compared to 14% of Midwestern isolates and 7% of Eastern 
isolates (Talan et al., 2000). 
The above data have led to the general feeling that trimethoprim and TMP-SMX 
are no longer acceptable choices for empirical therapy of UTI (Gupta et al., 1999). 
Ampicillin is no longer used since at least 30% of causative E. coli strains are ampicillin-
resistant (Talan et al., 2000). 
Due to this increased resistance to common antimicrobial treatments, a tum has 
been made from the prescription ofthese commonly empiric antimicrobial treatments, to 
a more potent cure. Enter the fluoroquinolones, whose low resistance rates have made 
them the operative therapeutic agents in UTI treatment. Fluoroquinolones are successful 
) 
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agents against Gram-negative bacilli, and their usage as antimicrobial agents has 
exploded, since their introduction in the 1980's. The most popular drug in this class, 
ciprofloxacin (Cipro), is the second most common antimicrobial prescribed in Spain and 
the fourth in the US (Ena et al., 1998). Its popularity stems primarily from its high 
success rates. In the aforementioned study by Talan et al. (2000), 47 of255 uropathogens 
were resistant to TMP-SMX while only one strain was resistant to Cipro, and none of the 
E. coli isolates exhibited Cipro resistance. Gupta et al. (1999) reported prevalence of 
resistance to Cipro of 0% to 2% in E. coli and less than 10% among all isolates 
combined. 
In the last year Infectious Disease Society of America (IDSA) mandates have 
recommended that the older fluoroquinolones-norfloxacin, ciprofloxacin and 
ofloxacin-become the standard empiric agent for UTI. But they are not without their 
faults. Fluoroquinolones in general are much more expensive than TMP-SMX, costing 
three to five dollars more per day (Talan et al., 2000; Bukharie and Saeed, 2001; 
O'Donnell et al., 2002). Furthermore, many in the scientific community are concerned 
that use offluoroquinolones as first-line therapeutic agents is contributing to the 
development of resistance to this valuable class of antimicrobials. In a study in Spain, 
where fluoroquinolones are used as first-line antimicrobials for community-acquired UTI, 
Ena et al. (1998) attributed ciprofloxacin-resistance in UTI E. coli isolates to prior 
treatment with fluoroquinolones. In that country, from 1990 to 1996 prescriptions for 
Cipro increased from 1392 grams to 3203 grams per year and E. coli resistance increased 
from 3% to 20%. In previous studies, there were significant increases in both in 
ciprofloxacin-resistant E. coli isolated from urine samples, and from bloodstream 
) 
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infections, which were attributed to regions with greater consumption of 
fluoroquinolones (Pena et al. 1995). O'Donnell et al. (2002), citing previous studies by 
Kresken et al. (1994) and Thompson et al. (1994), claim that there has been a progressive 
decrease in fluoroquinolone activity against clinical isolates in Europe. In the past 1 0 
years in the US, increasing numbers of reports of strains of E. coli, Klebsiella spp., and 
Enterobacter spp., with MIC's at or above the susceptibility breakpoints for the 
fluoroquinolones have caused increasing concern over their continued potency. In 
addition to the threat of resistance, ciprofloxacin, the most popular of the 
fluoroquinolones, causes drowsiness, increases theophylline levels, and is contraindicated 
for pregnant women. Ingestion of divalent and trivalent cations must be avoided during 
therapy. 
There is an alternative to TMP-SMX and Cipro in nitrofurantoin, a urinary-
specific treatment with high bacterial efficacy against many enteric gram-negative rods, 
except Pseudomonas aeruginosa and Proteus species (Gupta et al., 1999; O'Donnell et 
al., 2002). A UK study also found this antibacterial drug particularly effective against 
staphylococci and enterococci, species completely impervious to Cipro (Spencer et al., 
1994; Gupta et al., 1999; Bukharie and Saeed, 2001). Nitrofurantoin was originally 
introduced in 1968 and has been used as an antibacterial agent for over 3 5 years, with 
very low resistance development in target pathogens (Pelletier et al., 1992). In addition, 
nitrofurantoin is not as costly as Cipro. However, it must be taken 4 times daily (100 mg) 
for a 7-day time period as compared to Cipro's bi-daily (250mg) dose for three days. 
This difference raises issues of patient compliance and convenience (Gupta et al., 1999; 
O'Donnell et al., 2002). However, nitrofurantoin monohydrate/macrocrystals is a 
) relatively new formulation and may be taken twice daily, thereby addressing possible 
compliance problems (Spencer et al., 1994). 
Nitrofurantoin is not without its side effects. With long term use, it is a 
documented cause of pulmonary fibrosis and may cause intrahepatic cholestasis and 
hepatitis, and should be avoided in patients with creatinine clearance of less than 
60 mL/min (O'Donnell et al., 2002). But in clinical trials patients appear to experience 
less discomfort or adverse events with nitrofurantoin than trimethoprim or its derivatives 
(Spencer et al., 1994). 
Through overuse and misuse, resistance has emerged rapidly in some centers, 
necessitating, at the very least, a revision of current prescribing practices. Many 
physicians hold that to preserve their value as strong antimicrobial agents, 
:fluoroquinolones should not be used as an empiric therapy for UTI. Many more are of 
the opinion that Cipro is altogether unnecessary, that nitrofurantoin and TMP SMX are 
usually effective, and since cases are followed by bacterial analysis and culture to 
identify the infecting organism and its antimicrobial susceptibility, patients with resistant 
organisms may be identified and their prescriptions changed to a more powerful drug as 
needed. 
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The purpose of this study was to evaluate the efficacy of TMP-SMX, 
cipro:floxacin and nitrofurantoin on etiologic agents of urinary tract infections in the 
greater Chattanooga, Tennessee area. For comparison, cefazolin (a cephalosporin) and 
ampicillin (penicillin-derivative) resistance rates were also compared as representatives 
of the other major drug families. We also attempted to correlate resistance data to various 
parameters of the patient and infection, such as gender, age, previous UTI infection, 
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sexual activity, etc. It was hoped that a rubric could be created which would allow 
physicians to determine treatment success using various antimicrobials. 
Materials and Methods: 
Population 
The population for this study consisted of patients with community-acquired 
urinary tract infections, during February and March 2002, visiting various medical clinics 
in Hamilton and Bradley Counties, surrounding Chattanooga, Tennessee. A specific 
group of samples was obtained from Collegedale Medical Center, along with patient 
histories that might be used to study trends in uropathogen resistance patterns. 
Sample Collection 
At the Collegedale clinic, patients were advised on proper procedure to obtain a 
"clean catch" urine sample, and patients then collected urine into a sterile cup. The office 
lab technician then examined the samples under a microscope to confirm infection. 
Samples were refrigerated for up to four hours prior to transport to Memorial 
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Microbiological Labs at Memorial Hospital in Chattanooga, for identification of etiologic 
agent and antimicrobial profiling. 
Bacterial Culture and Identification 
Upon arrival at the lab, specimens were subjected to urinalysis in IRIS 
(International Remote Imaging System, Chatsworth, GA), to confirm infection and rule 
out cross-contamination by improper sample collection. IRIS is a digital microscope that 
shows images ofbacteria, WBC's, pH, fungi and other contaminants of urine. Cross-
contamination was usually indicated by Gram-positive cocci or diptheroids in the urine. 
Infection was confirmed by a leukocyte count greater than five WBC/cc. 
After urinalysis, samples suspected of infection were plated on both blood agar 
and MacConkey media and incubated for 18 hours at 37 degrees Celsius. Since it is an 
enriched medium, blood agar encourages the growth of a wide variety of possible 
bacterial pathogens whereas MacConkey media selects for Gram-negative bacteria, the 
most common agents of UTI infection. 
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Colony growth was examined after 18 hours of incubation. UTI was confirmed 
by a colony count greater than 10,000 colonies/mL. The most common causative agent 
of UTI, E. coli, is Gram-negative and therefore grows on both media types. In 
presumptive identification, a suspected E. coli colony on the MacConkey plates was 
tested for indole production using Endol reagent (Remel, Lenexa, KS). All suspected E. 
coli colonies were confirmed with the Bacticard Test (Remel) for indole (IND: p-
Dimethylaminobenzaldehyde) and MUG ( 4-methylumbelliferyl-(3-D-glucuronide ), which 
both yield positive results with E. coli by fluorescence under UV light. Pseudomonas 
also grows on both plates, so to confirm infection suspected colonies were tested for 
oxidase production (DIFCO, Grayson, GA). Streptococcal colonies appear only on the 
blood agar plate because they are Gram-positive. Suspected streptococci were strain 
typed by the Meritec Card Agglutination Test (Meridian Diagnostics, Cincinnatti, OH), 
because Group-B infections can cause miscarriages, and must be treated with immediacy 
and accuracy. 
) 
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Antimicrobial Susceptibility 
After diptheroid and yeast contamination or infection were ruled out by plate 
examination, suspensions of the suspected pathogens were prepared from colonies on the 
initial isolation plates, adjusted for proper turbidity (50 J.LA for Gram-negative growth and 
200 J.LA for Gram positive), and then loaded into individual cards for bacterial 
identification and antimicrobial susceptibility testing using the VITEK automated 
microbiology system (BioMerieux, Inc., Hazelwood, MO). The VITEK read each 
individual card, identifying etiologic agents and antimicrobial profiles, which the 
computer then printed out for each patient. 
Survey Instrument 
Patient history data was obtained for samples collected in Collegedale, in an 
attempt to examine the correlation between various UTI patient parameters and bacterial 
resistance. Patient histories were compiled with regard to age, sex, sexual activity, 
previous UTI and antimicrobial treatment, previous pelvic surgery, chronic illness and 
recent (within six months) antimicrobial treatment for each of the samples collected from 
patients visiting that clinic. 
Results 
A total of 108 samples were obtained from medical clinics in Hamilton and 
Bradley Counties, and microbial screening and antimicrobial susceptibility testing were 
performed according to the above-mentioned procedures at Memorial Hospital Labs. In 
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our study, eleven different etiologic agents were identified, the most common of which 
were Escherichia coli (54.6%), Klebsiella pneumoniae (13.9%), Pseudomonas 
aeruginosa (5.6%), and Proteus mirabilis (3.7%). Table 2 shows the percent composition 
of the most common isolates, comparing the data from the greater Chattanooga area to 
the smaller Collegedale sample. Other causative uropathogens included Citrobacter spp, 
Enterobacter spp, Klebsiella oxytoca, Providencia rettgerii, and Morganella morganii, 
each of which was responsible for less than 2% of the collected samples. 
Ofthe 108 isolates, 80 (74%) were from women. The mean age ofthe women in 
the sample was 52.4 years with a standard deviation of27.8 years. Incidence was highest 
for women between the ages of70 and 89, with almost 40% (31) ofthe 80 isolates 
coming from this age range. There were 28 men (26%) in the sample. The mean age for 
men was 66.3 years with a standard deviation of 16.0 years. Incidence was highest in 
men in the 80-89 age group, with 29% (8) of the 28 isolates occurring in men in this age 
category. Approximately 7.4% of the UTI isolates obtained were from children under 
age 10. Figure 1 illustrates the difference in UTI incidence between men and women, 
and between different age groups. 
Resistance was determined for each of the top four bacterial agents against five 
selected antimicrobials: ampicillin, cefazolin, ciprofloxacin, nitrofurantoin, and 
trimethoprim-sulfamethoxazole (Table 3). One hundred percent of the K. pneumoniae 
isolates were resistant to ampicillin, and 100% of the P. mirabilis were resistant to 
nitrofurantoin. One hundred percent of the P. aeruginosa isolates were resistant to all 
antimicrobial agents except Cipro. Together, these three bacterial species comprised 
23% of the total sample. Two of the E. coli isolates (1.7%) were resistant to Cipro and 
) 
11 
none showed resistance to nitrofurantoin, but 10.3% were resistant to TMP-SMX. These 
rates were compared to those calculated for the same geographical region by Sharp in 
2000 (Table 4). Overall, the efficacy of ampicillin and cefazolin rose by 4.2% and 2.3%, 
respectively, for E. coli. P. mirabilis showed no resistance to these drugs in 2002, 
whereas in 2000, this bacterium exhibited a 9% ampicillin and 3% cefazolin resistance 
rate. Nitrofurantoin was virtually ineffective on K. pneumoniae, P. aeruginosa, and P. 
mirabilis in both studies, while resistance to TMP-SMX increased more than two-fold in 
K. pneumoniae and P. mirabilis, but did not change significantly for E. coli and P. 
aeruginosa. Resistance to Cipro decreased by 0.3% for E. coli and by 2% forK. 
pneumoniae, but increased by 17% for P. aeruginosa and by 14% for P. mirabilis. 
In addition to calculating separate resistance rates for the most common bacteria, 
total resistance, regardless of infectious agent, for each of the five antimicrobials was also 
determined (Table 5). Resistance to ampicillin was 50%, to nitrofurantoin 20% and to 
TMP-SMX 17%. Resistance to Cipro was the lowest, at 8%. Eleven isolates were 
obtained from children under eleven years of age; four were multi-resistant organisms 
and one of these was susceptible only to Cipro. 
Resistance data was also correlated, irrespective of etiologic agent, to gender 
(females-Table 6, Figure 2; males-Table 7, Figure 3) according to age. The mean 
resistance rate in females was calculated at 27.4% (Table 6). Ampicillin resistance was 
high in all groups (Table 6), peaking in the 20-29 age group (89%) and 60-69 (75%)age 
group (Figure 2). TMP-SMX resistance was present in all but the 50-59 and 90-99 age 
groups, peaking at 25% in the 60-69 year-olds. Cipro was the only antimicrobial whose 
resistance remained below 20% in all categories, but even this agent incurred 17% 
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resistance in the 40-49 year-olds. Nitrofurantoin resistance was present in all but the 30-
39 and 50-59 year-olds and reaches or exceeds 20% in half the categories, peaking at 
27%, in the 70-79 age group (Figure 2). 
In the males, mean resistance was calculated at 42.4% (Table 7). No resistance 
was observed in the 20-29 or 30-39 age groups, and only ampicillin resistance was 
present in the 40-49 age group (Table 7). Ampicillin resistance was 100% in 60-69 year-
olds, and remained high in all over-50 patients. No Cipro, cefazolin or nitrofurantoin 
resistance was present in any patient under 60 year of age. TMP-SMX resistance 
appeared in the 50-59 age group and steadily increased to its peak (38%) in patients 
between 80 and 89 years of age (Figure 3). Resistance to all five antimicrobials was 
observed in the last three age groups (60-69, 70-79 and 80-89), commonly reaching 30-
40%, 10% higher than the mean resistance rate in women (Figure 2). Isolates from the 
60-69 age category exhibited the second highest resistance rates; 50% were resistant to 
nitrofurantoin. Again, Cipro resistance was the lowest over all, but its lowest value, in the 
70-79 age group, was still 14%. 
The Collegedale Medical Center yielded a very small sample size. 32 UTI 
patients were identified during the study and of these, 15 were excluded due to 
contamination or lack of growth. Of the 17 remaining samples, 13 were from women and 
four were from men. The mean age of the women was 52.7 years with a standard 
deviation of 18.4 years, and the mean age for men was 64.5 years with a standard 
deviation of 15.9 years. Figure 4 illustrates the difference in UTI incidence between men 
and women and between age groups from the Collegedale sample. 
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Eleven (65%) in the sample were sexually active, eleven (65%) had been 
diagnosed with a previous UTI, six (35%) had undergone pelvic surgery at some point 
prior to infection, four (24%) were classified as "chronically ill" and ten (59%) had taken 
an antimicrobial in the last six months. All the antimicrobials taken by these ten patients 
were either ampicillin or quinolone derivatives. 
Nine (53%) ofthe 17 Collegedale samples showed resistance, but only to 
nitrofurantoin (29%) and ampicillin (41%), with one exception in the single 
Pseudomonas aeruginosa isolate in the sample, which was only susceptible to Cipro. Of 
the nine resistant isolates, 77% had had a previous UTI, and 67% had received antibiotic 
therapy in the last six months. 
As with the Chattanooga sample, resistance rates for the top four uropathogens 
were calculated for each of the five selected antimicrobials (Table 8). All P. aeruginosa 
isolates were resistant to every antimicrobial drug except Cipro. P. mirabi/is was 
resistant only to nitrofurantoin (100%) and K. pneumoniae to ampicillin (100%) and 
nitrofurantoin (67%). These isolates amounted to five of the 17 samples. E. coli was 
only resistant to ampicillin (33%) and no pathogens were resistant to Cipro. 
The Collegedale sample was also divided by sex, for comparison of UTI 
incidence between sexes and according to age groups (Figure 4). Only four of the 17 
isolates were from men, and each one was from a different age group. Incidence was 
highest in women between the ages of 40 and 59, with half (8) of the 17 isolates falling 
into this age range. 
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Discussion 
The Chattanooga and Collegedale samples were similar in composition, yielding 
E. coli, K pneumoniae, P. aeruginosa and P. mirabilis as the top four causative agents 
(Table 2). However, the very small sample size of the Collegedale group makes 
comparison difficult. Similar to the previous year's studies by Mathai et al. (200 1) and 
Bukharie and Saeed (2001), E. coli was the most common etiologic agent in both of our 
samples, while the order and incidence of other common uropathogens seems to vary 
from study to study (Tables 1 and 2). 
The Chattanooga sample was primarily used to relate sex and age to UTI 
incidence as well as to antibiotic resistance. Examination reveals definite differences not 
only in incidence between the sexes, but between age groups within the sexes (Figure 1). 
Women are much more susceptible to urinary tract infection because of a much shorter 
urethra, which enables bacteria to invade and infect more easily. As would be expected, 
the sample of women with UTI is more than twice that of the male sample. It is 
interesting to examine the UTI incidence in children in our study. Urinary tract 
infections typically occur in as many as 5% of female and 1% to 2% of male children 
(Porth, 1998). Our sample yielded only female children, but incidence in this age group 
was quite high, at 7 .4%. The increase in UTI incidence in women in their twenties can be 
attributed to sexual activity, as studies mentioned previously and the results from the 
Collegedale clinic (65% were sexually active) have substantiated. Women in their 
thirties and forties are typically married, have fewer sexual partners, or are simply more 
responsible about gynecologic hygiene, which may explain the lower UTI incidence in 
these groups. But it must be noted that from the forties on, our study shows a steady 
increase of UTI in both males and females (Figure 1). This may be attributed to 
menopause, during which time the vaginal area becomes less acidic, and thus more 
susceptible to bacterial infection. Fewer UTI's occur in men due to the longer urethra 
and more difficult access to the urinary tract, reducing the chance of infection. In both 
men and women, UTI incidence steadily increased with age (Figure 1 ). More study is 
needed to determine the factors responsible for this trend. 
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At first glance, the antimicrobial resistance to the five selected therapeutic agents 
in this study exhibits several differences from that obtained by Sharp (2000) for the 
Chattanooga area. Initially, rates appear to be higher in 2002 than they were two years 
ago (Tables 3 and 4). K pneumoniae, P. aeruginosa and P. mirabilis exhibit alarmingly 
high resistance (100 %) to all antimicrobials but Cipro. Fortunately, these bacteria 
comprise only 23% ofuropathogens in this study, but these are still disturbing results. E. 
coli is sufficiently susceptible to Cipro and nitrofurantoin, but shows higher resistance to 
TMP-SMX, a trend that has caused the IDSA to switch to Cipro as the first-line empiric 
agent in UTI treatment. Ampicillin's and Cefazolin's efficacy seems to have improved 
for E. coli and P. mirabilis, while that ofTMP-SMX has decreased, in some cases by 
more than 14 percent. Nitrofurantoin appears to have lost its effectiveness in both studies 
(only E. coli is susceptible), but resistance to Cipro was zero in both studies, except in 
Pseudomonas. However, once the sample size is taken into account, the results do not 
appear to be significantly different. The data compiled in the 2000 study comprised all of 
the resistance data for all of the bacterial isolates obtained in the Chattanooga area in 
2000, which included, but were not limited to, urinary tract infections. Our study looked 
only at UTI's occurring during February and March of 2002. Despite this difference in 
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sample type, the resistance rates in these two studies are comparable. The difference 
between the efficacy of Cipro and the other antimicrobials is noteworthy. In both studies, 
Cipro was undoubtedly the more powerful antimicrobial agent, especially against 
Pseudomonas, which is virtually impervious to anything else. 
Part of our purpose in this study was to create a rubric, if possible, for local 
physicians to estimate a given drug's success, regardless of the infectious agent. 
Calculations revealed that irrespective of gender, age group and other factors, there was 
considerably less resistance to Cipro (8%) than the other therapeutic agents. Even 
resistance to nitrofurantoin (20%) is disappointing and ampicillin (50%) is virtually 
useless (Table 5). 
The analysis of resistance patterns with regard to the age group of the patient in 
the Chattanooga sample of women (Table 6, Figure 2) yielded a mean resistance rate of 
approximately 27.4%, which is higher than a desirable value for effective antimicrobial 
treatment. Age does appear to be a factor in UTI incidence, but does not seem to affect 
the development of resistance in women. All the antimicrobials experience varying 
degrees of resistance in all age groups, but Cipro is generally more powerful against the 
common uropathogens. 
The mean resistance rate in men with UTI's was 42.4%, which is considerably 
higher (approx. 15%) than that of women. Unlike women, only bacteria from older men 
exhibit resistance. Age does appear to be a factor in resistance development, as exhibited 
by the lack thereof in the younger age groups. This might be attributed to a lower anti-
infective drug exposure. Young men are typically healthy, and require antibiotic 
treatment only very rarely, therefore they are less likely to acquire or develop resistant 
bacteria. But herein lies an anomaly. In theory, younger women ought to need less 
antibiotic treatment than older women as well. However, the sample size was too small 
(28) to draw any firm conclusions. 
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Generally, resistance seems to be more prevalent in older patients, which might be 
expected, since the older a patient is, the more he/she has been exposed to antimicrobial 
agents, and the more chance he/she has had to develop resistance. But the Chattanooga 
sample presented another alarming anomaly. Of the eleven isolates obtained from 
children under 11 years of age, four were resistant organisms, and one of those was 
susceptible only to Cipro. Since the samples were obtained from outpatient facilities or 
physician offices, it is safe to assume these are not critically ill children with nosocomial 
infections. However, without patient history, it is impossible to delineate the avenues 
through which these children have already acquired such alarmingly resistant organisms. 
Still, the spread of resistance in such young patients is a warning sign of the widespread 
resistance and the continual danger that commonly prescribed antimicrobials will soon be 
rendered insignificant. 
The Collegedale sample seemed to have a lower incidence of resistant organisms. 
Isolates were resistant only to nitrofurantoin and ampicillin, except the single P. 
aeruginosa isolate, which was susceptible only to Cipro. Due to the small sample size, 
however, this conclusion is misleading. A larger study must be done to confirm the 
elevated uropathogen susceptibility in this area. 
The difference between UTI incidence in males and females and within certain 
age groups also slightly varied between the Collegedale and Chattanooga samples 
(Figures 1 and 4). Only four (24%) ofthe 17 isolates were from men, and each one was 
) 
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from a different age group, thus, no firm conclusions may be drawn from this group. In 
Collegedale, the women with the highest UTI incidence were those between the ages of 
40 and 59; half of the isolates fell into this age range. This differs from the Chattanooga 
sample, in which the highest incidence of UTI's in women occurred between the ages of 
70 and 89, and comprised only 40% of the entire sample. Here again, the difference may 
simply be to the small sample size obtained in Collegedale. Without further study, it is 
impossible to determine otherwise. 
Though the clinic sample was very small and the results statistically insignificant 
because of this, it is sufficient to draw some preliminary conclusions. Sexual activity 
does appear to correlate with the contraction of a UTI, but not to antibiotic resistance. 
Chronic illness and pelvic surgery may be linked to resistance development, since all 
isolates from patients in both of these categories were resistant to at least one 
antimicrobial. In either case, a patient would receive antibiotic therapy, whether to cure 
infection (chronic) or to prevent it (surgery), thereby exposing normal flora and 
opportunistic pathogens to antibiotics without eliminating them, and thus spreading 
resistance. Similarly, over two-thirds of the patients with resistant organisms had also had 
a previous UTI and/or antibiotic therapy within the last six months. This too may point 
to a link between previous UTI infection and resistance development. Diagnosis with a 
previous UTI would result in antibiotic therapy, thereby increasing the possibility of drug 
resistance. The same would follow for any other infection and treatment the patient 
acquired in the previous six months. 
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Conclusion 
Though sample sizes were not ideal, several important conclusions may be drawn 
from this study about the general trends in resistance in the greater Chattanooga area to 
the five anti-infective drugs studied. Ampicillin is virtually useless in treating UTI's. 
Resistance is present, to varying degrees, in virtually all bacterial UTI agents, in nearly 
all age groups. Cefazolin may still be useful in some areas, but its efficacy has been 
reduced to comparison purposes in this region. There is neither high resistance nor high 
susceptibility to this drug. Though a few age groups appeared to lack or have lowered 
resistance to nitrofurantoin and TMP-SMX, the small sample sizes in these groups 
prevents us from concluding that these drugs may be effective in these age categories. 
Both may still be useful when the antibiotic profile of an infectious agent is known, but 
they are inadequate to use as empiric broad-spectrum antibiotics. Cipro is undoubtedly 
the most potent agent, and it is clear why the IDSA had required the switch from TMP-
SMX to Cipro as a first-line UTI therapeutic agent. However, Cipro is no longer 
infallible; even though it is consistently the most powerful treatment option, resistance to 
it is rising. 
Further research needs to be conducted to draw firm conclusions tying 
extenuating factors to antibiotic resistance. First, a more in-depth version of the 
Collegedale clinic study is needed, investigating patient history and relating previous 
antibiotic treatment, previous UTI, chronic illness and sexual activity more conclusively 
to incidence and resistance. Factors contributing to resistance in children might also be 
worthy of investigation. Whatever the mode or medium, it is clear that more research 
must be done, not only to gauge the continued potency of the common empiric agents, 
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but to better prevent the spread of resistance and to prepare for the eventual necessity of 
newer and more powerful drugs. 
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Table 1. Comparison of Incidence of Specific 
Uropathogens in 2001 Studies by Mathai, et al., and 
Bukharie and Saeed. 
Mathai Bukharie 
n=1550 n=461 
E. coli 46.9 
Enterococcus spp 12.8 
Klebsiella spp 11.0 
Pseudomonas aeruginosa 7.5 
Proteus mirabilis 5.0 
Coagulase-negative Streptococci 3.4 
Group B Streptococci
Table 2. Percentage Composition of Samples 
Obtained From Chattanooga Area (Memorial 
Labs) and Collegedale Medical Center, 
February and March 2002 
Chattanooga CMC 
n=108 n=17 
E. coli 54.6 52.9 
K pneumoniae 13.9 17.6 
Ps. aeruginosa 5.6 5.9 
Prot. mirabilis 3.7 11.8 
Other* 16.8 11.8 
*includes various Citrobacter spp, Enterobacter 
spp, Klebsiella oxytoca, Providencia rettgerii, 
and Morganella morganii. 
58 
13 
21 
3 
3 
Table 3. Percentage of Isolates Resistant to Selected Antimicrobial Agents in 
Chattanooga Area (Memorial Labs), February-March, 2002. 
E. coli K. pneumoniae Ps. aeruginosa Prot. mirabilis 
n=59 n=15 n=6 n=4 
Ampicillin 28.8 100 100 0 
Cefazolin 1.7 0 100 0 
Ciprofloxacin 1.7 0 50 25 
Nitrofurantoin 0 46.7 100 100 
Trimeth/Sulfa 10.3 13.3 100 25 
) 
Table 4. Percentage of Isolates Resistant to Selected Antimicrobial 
Agents in 2000, S. Sharp. Memorial Hospital, Chattanooga, TN. 
E. coli K. pneumoniae Ps. aeruginosa Prot. mirabi/is 
n=2900 n=B05 n=768 
Ampicillin 33 99 99 
Cefazolin 4 2 100 
Ciprofloxacin 2 2 33 
Nitrofurantoin 1 44 100 
Trimeth/Sulfa 12 7 97 
Table 5. Percent Resistance to Selected Microbial Agents, 
Irrespective to Etiologic Agent, Memorial Labs, 2002. 
n=420 
9 
3 
11 
98 
9 
Ampicillin Cefazolin Ciprofloxacin Nitrofurantoin Trimeth/Sulfa 
n=54 n=20 n=9 n=22 n=18 
50 19 8 29 18 
Table 6. Resistance Rates by Age Group of Female Population (n=80), 
Irrespective to Etiologic Agent, from Memorial Labs, 2002. 
Age Ampicillin Cefazolin Ciprofloxacin Nitrofurantoin Trimeth/Sulfa 
0-9 25 0 0 13 13 
10--19 40 20 0 20 20 
20-29 89 22 11 22 11 
30-39 40 0 0 0 20 
40-49 33 33 17 17 17 
50-59 57 0 0 14 0 
60-69 75 25 13 25 25 
70-79 27 13 0 27 13 
80-89 31 25 13 6 13 
90-99* 100 0 0 0 0 
*Only one sample was obtained within this age group, therefore the resistance 
to ampicillin is misrepresented as more extreme than is probable. 
Table 7. Resistance Rates by Age Group of Male Population (n=28), Irrespective 
to Etiologic Agent, from Memorial Labs, 2002. 
Age Ampicillin Cefazolin Ciprofloxacin Nitrofurantoin Trimeth/Sulfa 
20-29* 0 0 0 0 0 
30-39 0 0 0 0 0 
40-49 50 0 0 0 0 
50-59 60 0 0 0 20 
60-69 100 25 25 50 25 
70-79 43 29 14 43 29 
80-89 88 50 25 50 38 
*No male samples were obtained from patients younger than 20, or older than 89. 
Table 8. Percentage of Isolates Resistant to Selected Antimicrobial Agents from 
Collegedale Medical Center, February-March, 2002. 
E. coli K. pneumoniae Ps. Aeruginosa Prot. Mirabilis 
n=9 n=3 n=1 n=2 
Ampicillin 33 100 100 0 
Cefazolin 0 0 100 0 
Ciprofloxacin 0 0 0 0 
Nitrofurantoin 0 67 100 100 
Trimeth/Sulfa 0 0 100 0 
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